On Tuesday 30 March, the European Commission began consultations on the review of medicines legislation, as it committed to do in its November 2020 pharmaceutical strategy(see EUROPE B12609A10). Stakeholders can comment on its initial impact assessment until 27 April.
The consultation focuses on Directive 2001/83/EC and Regulation 726/2004. In particular, the Commission wants to know whether this framework responds to the problems identified by the Pharmaceutical Strategy, whether it is...